| 前收盘价格 | 0.000 |
| 收盘价格 | 0.000 |
| 成交量 | 520,795 |
| 平均成交量 (3个月) | 11,388,190 |
| 市值 | 426,166 |
| 市盈率 (P/E TTM) | 0.000 |
| 股市价格/股市净资产 (P/B) | 0.030 |
| 营业毛利率 | -159.67% |
| 营业利益率 (TTM) | -48.80% |
| 稀释每股收益 (EPS TTM) | -14.43 |
| 季度收入增长率 (YOY) | 44,049.30% |
| 总债务/股东权益 (D/E MRQ) | 103.14% |
| 流动比率 (MRQ) | 0.110 |
| 营业现金流 (OCF TTM) | -3.77 M |
| 杠杆自由现金流 (LFCF TTM) | 6.67 M |
| 资产报酬率 (ROA TTM) | -17.50% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Health Information Services (US) | 看跌 | 混合的 |
| Health Information Services (全球的) | 看跌 | 混合的 | |
| 股票 | FOXO Technologies Inc. | - | - |
AIStockmoo 评分
| 分析师共识 | -2.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 0.0 |
| 平均 | -0.38 |
|
FOXO Technologies Inc. engages in epigenetic biomarker underwriting technology and consumer engagement platform service business in the United States. It operates through two segments, FOXO Labs and FOXO Life. The company applies automated machine learning and artificial intelligence technologies to discover epigenetic biomarkers of human health, wellness, and aging. It offers FOXO Labs, a commercializing proprietary epigenetic biomarker technology enables the adoption of saliva-based health and wellness biomarker solutions for underwriting and risk assessment; and FOXO Life, a sales and distribution platform focused on recruiting independent life insurance agents to sell life insurance with the Longevity Report. The company was founded in 2020 and is based in Minneapolis, Minnesota. FOXO Technologies Inc. is a subsidiary of FOXO Management LLC. |
|
| 部门 | Healthcare |
| 行业 | Health Information Services |
| 内部持股比例 | 1.75% |
| 机构持股比例 | 0.45% |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合